Press Room

News / Jul 14, 2022

Hovione releases its 4th Sustainability Report

The sustainability report covers the fiscal years 2019 and 2020

Hovione sustainability report 2019-2020 cover

The Sustainability Report 2019-2020 is published under the title “Elements of the future. For tomorrow and beyond, no matter what.” 

This is the fourth Sustainability Report published by Hovione and is intended to demonstrate our accountability to our stakeholders by communicating the company's progress on Environmental, Social and Governance (ESG) topics. The Report also reflects our alignment to the United Nations Sustainable Development Goals (UN SDGs). 

The report has been prepared in line with the Global Reporting Initiative Standards content and quality principles, to ensure information accuracy, clarity and reliability. These standards enable greater transparency and accountability of organizations, by enhancing global comparability and quality of information around ESG performance. The information covers all our owned manufacturing and research facilities worldwide and the data presented is global.

As a company, we want to manufacture and deliver medicines of the highest quality to the patients aligned with our commitment to operating a sustainable business. We have as reference the highest standards of safety and environmental performance, staffed by an engaged and diverse workforce.

Being “In it for life” means that we are committed to protecting our people, our communities, our partners and the environment around us.

 

Find more about Sustainability at Hovione

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026